A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Recruiting · NCT06854640 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy | Hemic and Lymphatic Diseases, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, blood coagulation disease, cardiovascular disorder, disseminated intravascular coagulation, hematologic disorder, hemorrhagic disease, thrombophilia, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-23 | NCT06854640 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bayer | 178 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.